Palavras-chave
neoplasias meníngeas
neoplasias encefálicas
neoplasias de la mama
metástasis de la neoplasia.
Como Citar
Resumo
Las metástasis en la fosa posterior con asociación leptomeníngea en pacientes con cáncer de mama son infrecuentes. La supervivencia promedio posterior al tratamiento es de 4 a 6 meses. En la literatura se han descrito diferentes opciones terapéuticas para este tipo de lesiones. La localización en la fosa posterior puede ser compleja, llegar a afectar estructuras esenciales del sistema nervioso central (SNC) y requerir un manejo oportuno para evitar complicaciones que empeoran el pronóstico y la supervivencia. Este artículo presenta el caso de una paciente de 57 años de edad con una lesión metástasica única en el aspecto superior del vermis cerebeloso con infiltración leptomeníngea focal asociada, que fue manejado con radiocirugía de dosis única. En el seguimiento a 10 meses se documentó mejoría clínica y neurológica, sin evidencia de enfermedad en SNC por imágenes. Adicionalmente, se revisó la literatura al respecto.
Patchell RA. The management of
brain metastases. Cancer Treat Rev.
;29(6):533-40.
Suh JH. Stereotactic radiosurgery for
the management of brain metastases. N
Engl J Med. 2010;362(12):1119-27. doi:
1056/NEJMct0806951
de la Monte SM, Hutchins GM, Moore
GW. Estrogen and progesterone receptor in
prediction of metastasic behavior of breast
carcinoma. Am J Med 1984;76:11-7.
Scott B, Kesari S. Leptomenigeal metastases
in breast cancer. Am J Cancer Res.
;3(2):117-26.
Frisk G, Svensson T. Incidence and time
trends of brain metastases admissions
among breast cancer patients in Sweden.
Br J Cancer 2012 may 22;106:1850-3.
doi: 10.1038/bjc.2012.163.
Kesari S, Batchelor TT. Leptomeningeal
metastases. Neurol Clin. 2003 Feb;21:
-66.
Altundag K, Bondy ML, Mirza N, Rivera
E. Clinico-pathologic characteristics
and prognostic factors in 420 metastasic
breast cancer patients with central
nervous system metastases. Cancer.
;110:2640-7.
Boogered W, van den bent MJ. The relevante
of intraventricular chemotherapy
for Leptomeningeal metastases in breast
cáncer. Eur J Cancer. 2004;40:2726-33.
Hitchins RN, Woods RL. A prospective
randomized trial of single-agent versus
combinación chemotherapy in meningeal
carcinomatosis. J Clin Oncol.
;5:1655-62.
Slimane K, André F, Delaloge S, Dunant
A, Perez A, Grenier J, et al. Risk factors
for brain relapse in patients with metastatic
breast cancer. Ann Oncol. 2004
Nov;15(11):1640-4. doi: 10.1093/annonc
/mdh432
Gauthier H, Guilhaume MN, Pierga JY.
Survival of breast cancer patients with
meningeal carcinomatosis. Ann Oncol.
Nov;21:2183-7.
Rudnicka H, Niwinska N, Murawka M.
Breast cancer leptomeningeal metastases-
the role of multimodality treatment. J
Neurooncol. 2007;84(1):57-62.
Clarot F, Philippin-Lauridant G, Ouvrier
MJ, Nakry T, Laberge-Le-Couteulx S,
Guillemet C, et al. Clinical improvement
and survival in breast cancer leptomeningeal
metastases correlate with the cytologic
response to intratecal chemotherapy.
J Neurooncol. 2009;95(3):421-6. doi:
1007/s11060-009-9940-2
Hermann B, Hültenschmidt B, Sautter-
Bihl ML. Radiotherapy of the neuroaxis
for paliative treatment of leptomeningeal.
Strahlenther Onkol. 2001;177(4):195-9.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.